CFC
ALXN

Coyle Financial Counsel’s Alexion Pharmaceuticals ALXN Stock Holding History

Coyle Financial Counsel’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-21
Closed -$3K – 314
2018
Q2 		$3K Buy
+21
New +$2.45K ﹤0.01% 267

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Coyle Financial Counsel's ALXN Position: Q3 2018 in Review

Coyle Financial Counsel sold out of Alexion Pharmaceuticals (ALXN) in Q3 2018, closing a stake of 21 shares — an estimated $3K sold.

Coyle Financial Counsel first reported a position in ALXN in Q2 2018 and held it in 1 quarter. The position peaked at $3K in Q2 2018. 584 funds tracked by Wall St. Rank hold ALXN as of Q3 2018.

  • Coyle Financial Counsel reported no remaining Alexion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Coyle Financial Counsel sold 21 Alexion Pharmaceuticals shares in Q3 2018, an estimated $3K.
  • Coyle Financial Counsel first reported a position in Alexion Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Coyle Financial Counsel's Alexion Pharmaceuticals position peaked at $3K in Q2 2018.
  • 584 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2018.

Based on Coyle Financial Counsel's 13F filing for Q3 2018, filed 13 Nov 2018.